Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Google Secures Pentagon AI Deal for Classified Projects 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
NEW YORK, April 26, 2017 -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, announced today that Dr. Lan Huang, Ph.D., Chairman and CEO, will present at Joseph Gunnar's Pioneers 2017 Conference on Tuesday, May 2, 2017 at 10:30 am ET in the Lotus East Room of the Mandarin Oriental Hotel, 80 Columbus Circle at 60th Street in New York City.
Investors attending the conference who wish to meet with management for a one-on-one meeting should notify their appropriate contact or e-mail [email protected].
For more information and registration, please visit the conference website.
About BeyondSpring
BeyondSpring is a global clinical stage biopharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with Fred Hutchinson Cancer Research Center and University of Washington. BeyondSpring’s lead asset, Plinabulin, is in a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced neutropenia. BeyondSpring has a seasoned management team with many years of experience bringing drugs to market.
About Plinabulin
Studies on Plinabulin's method of action indicate that Plinabulin activates GEF-H1, a guanine nucleotide exchange factor. GEF-H1 activates downstream transduction pathways leading to the activation of the protein c-Jun. Activated c-Jun enters the nucleus of dendritic cells to upregulate immune-related genes, which contributes to the up-regulation of a series of genes leading to dendritic cell maturation, T-cell activation and other effects that prevent neutropenia.
Investor Relations: Garth Russell / Allison Soss KCSA Strategic Communications 212.896.1250 / 212.896.1267 [email protected] / [email protected] Media Relations: Caitlin Kasunich / Amy Singh KCSA Strategic Communications 212.896.1241 / 212.896.1207 [email protected] / [email protected]
